Press release content from Business Wire. The AP news staff was not involved in its creation.
Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease
July 24, 2021 GMT
SAN JUAN CAPISTRANO, Calif. (BUSINESS WIRE) Jul 24, 2021
Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that all primary and secondary endpoints of an ex-U.S. vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, M.D., at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) Annual Meeting in Las Vegas. 1
New Prospective Study Shows Significant Reduction In Reports Of Postoperative Halos From Patients Treated With TearScience LipiFlow Treatment Prior To Bilateral Cataract Surgery - Press Release
wiredprnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wiredprnews.com Daily Mail and Mail on Sunday newspapers.
New Prospective Study Shows Significant Reduction In Reports Of Postoperative Halos From Patients Treated With TearScience LipiFlow Treatment Prior To Bilateral Cataract Surgery
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U S Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.